To stent or not to stent aortic dissection: good news for a chosen few, but who?

Type B aortic dissections: treating the many to benefit the few?

PURPOSE

It is now more than a decade since aortic stent-grafts were introduced clinically to provide a less invasive and potentially less harmful therapeutic option to treat type B aortic dissections. However, recent publications on best medical treatment and quality of life in patients with chronic type B dissection support conservative treatment due to the low incidence of aneurysm formation, rupture, and disease-related complications. Against this backdrop, we analyzed our experiences and now discuss whether the availability of endografts allowed us to change indications toward a more aggressive endovascular approach to acute and non-complex type B dissections, seeking to determine which patients we should treat and which ones we should observe.

METHODS

Between 1997 and 2008 in our institution in Heidelberg, we treated 172 patients with acute and chronic type B dissections, most (n = 118, 69%) conservatively. However, 54 patients (40 men; mean age 57 years, range 30-82) underwent endovascular repair; 43% (n = 23) were emergency cases. Patients were followed periodically with computed tomographic angiography.

RESULTS

Correct stent-graft deployment was achieved in 50 (93%) patients; the left subclavian artery was intentionally covered in 30 (55%) cases. Two carotid-subclavian bypass grafts were performed at the time of the endovascular repair due to partial coverage of the left common carotid artery. The perioperative complication rate was 19% (n = 10), but there were no neurological sequelae. The 30-day mortality rate was 11% (n = 6). Over a mean 32.1+/-25 months, 4 other patients died (18.5% overall mortality rate); survival estimates by Kaplan-Meier analysis were 80.4% and 66.1% after 1 and 5 years, respectively. Complete false lumen thrombosis was observed in 32 (60%) and a persisting completely patent false lumen in 3. The aortic expansion rate was 31% (17/54) overall. No difference was found between acute and chronic dissections in terms of survival (p = 0.247).

CONCLUSION

Despite a minimally invasive approach, complication and mortality rates for endovascular therapy of type B aortic dissections are considerable. Endografting is limited to symptomatic patients and those with chronic large aneurysmal expansion. At this stage in stent-graft development, asymptomatic patients benefit more from conservative treatment.

Thoracic aortic endografting is the treatment of choice for elderly patients with thoracic aortic disease

OBJECTIVE

To assess the effect of age on outcomes following thoracic aortic endografting.

SUMMARY BACKGROUND DATA

Endograft therapy for thoracic aortic disease is rapidly evolving. This therapy is less invasive, and elderly patients with significant medical comorbidities are more frequently referred for endografting. We hypothesized that elderly patients over the age of 75 have worse outcomes after thoracic endografting than patients under the age of 75.

METHODS

We retrospectively reviewed the charts of the first 42 patients who underwent endografting for thoracic aortic pathology. Charts were reviewed for demographics, comorbid conditions, perioperative complications and death, endoleaks, and results at 3, 6, and 12 months. Preexisting medical conditions were also evaluated to determine if any patient characteristics were associated with adverse outcomes. Perioperative morbidity included cardiac, pulmonary, renal, hemorrhagic, and neurologic (stroke and spinal cord injury) complications.

RESULTS

Twenty-four patients were under the age of 75, and 18 patients were 75 or older. Baseline demographics and comorbidities were similar between the 2 groups. There were no differences in operative time, length of stay, perioperative mortality, or the incidence of significant complications between the 2 age groups. Gender, however, was associated with a statistically significant difference between the occurrence of complications, with more women experiencing complications than men (P = 0.026, relative risk = 2.36). One patient (age >75 years) in the entire cohort of 42 (2.4%) suffered a spinal cord injury. At 3 months, endoleaks were more common in the older age group (P = 0.059).

CONCLUSION

Endograft therapy for thoracic aortic disease can be performed safely in elderly patients with no significant increase in perioperative morbidity or mortality compared with younger patients. Female gender is associated with a higher likelihood of perioperative complications, regardless of age. The overall incidence of spinal cord injury is very low. Endograft therapy, when anatomically possible, is the treatment of choice for thoracic aortic disease in elderly patients.